Trials / Terminated
TerminatedNCT02079480
Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects
Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986090 in Healthy Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 130 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-986090 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986090 | |
| DRUG | Placebo matching with BMS-986090 | |
| DRUG | Keyhole limpet hemocyanin |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2014-03-05
- Last updated
- 2016-05-12
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02079480. Inclusion in this directory is not an endorsement.